Actinium Pharmaceuticals, Inc (ATNM)

Price$1.08

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-29.66%

Price vs S&P 500 (4W)-17.55%

VGM Score47.91

Market Capitalization$33.88M

All Metrics

Book Value / Share (Quarterly)$0.07

P/TBV (Annual)1.76x

Revenue Growth (3Y)-55.63%

Cash Flow / Share (Quarterly)$-0.73

Price vs S&P 500 (YTD)-28.75%

Net Profit Margin (TTM)-5701.11%

EPS (TTM)$-0.75

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-0.75

EPS (Annual)$-1.09

ROI (Annual)-431.96%

Net Profit Margin (5Y Avg)-5775.48%

Cash / Share (Quarterly)$1.34

ROA (Last FY)-65.45%

Revenue Growth TTM (YoY)11.11%

EBITD / Share (TTM)$-0.82

ROE (5Y Avg)-153.37%

Operating Margin (TTM)-6324.44%

Cash Flow / Share (Annual)$-0.79

P/B Ratio14.71x

P/B Ratio (Quarterly)13.55x

Net Income / Employee (Annual)$-1,355,500

EV / Revenue (TTM)-91.54x

Net Interest Coverage (TTM)-10.19x

ROA (TTM)-43.39%

EPS Incl Extra (Annual)$-1.09

Current Ratio (Annual)6.20x

Quick Ratio (Quarterly)5.73x

3-Month Avg Trading Volume0.16M

52-Week Price Return-36.09%

Revenue / Employee (TTM)$3,600

Tangible BV / Share (Quarterly)$1.59

P/S Ratio (Annual)376.50x

Asset Turnover (Annual)0.00x

52-Week High$1.95

Operating Margin (5Y Avg)-5858.31%

EPS Excl Extra (Annual)$-1.09

CapEx CAGR (5Y)-16.29%

Tangible BV CAGR (5Y)37.21%

26-Week Price Return-21.74%

Quick Ratio (Annual)6.02x

13-Week Price Return-8.47%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.89x

Enterprise Value$-8.24M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-40.95%

Revenue / Employee (Annual)$3,600

Pretax Margin (Annual)-37652.22%

Cash / Share (Annual)$1.54

3-Month Return Std Dev71.87%

Net Income / Employee (TTM)$-938,800

ROE (Last FY)-432.56%

Net Interest Coverage (Annual)-30.00x

EPS Basic Excl Extra (Annual)$-1.09

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.75

ROI (TTM)-218.42%

P/S Ratio (TTM)376.50x

Pretax Margin (5Y Avg)-5775.48%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.59

Price vs S&P 500 (52W)-60.46%

Year-to-Date Return-20.59%

5-Day Price Return-8.47%

EPS Normalized (Annual)$-1.09

ROA (5Y Avg)-46.97%

Net Profit Margin (Annual)-37652.22%

Month-to-Date Return-14.29%

Cash Flow / Share (TTM)$-1.89

EBITD / Share (Annual)$-1.16

Operating Margin (Annual)-40274.44%

ROI (5Y Avg)-153.21%

EPS Basic Excl Extra (TTM)$-0.75

P/TBV (Quarterly)2.69x

P/B Ratio (Annual)5.42x

Pretax Margin (TTM)-5701.11%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)-16.73%

Beta0.01x

P/FCF (Annual)4.09x

Revenue / Share (TTM)$0.00

ROE (TTM)-218.67%

52-Week Low$0.95

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.18est. -0.24

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATNMActinium Pharmaceuticals, Inc	—	B	D	$1.08
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Actinium Pharmaceuticals develops targeted radiotherapies for hard-to-treat cancers using monoclonal antibodies to deliver radioisotopes directly to cancer cells. The company's portfolio includes Iomab-B for hematopoietic stem cell transplantation and Actimab-A, in clinical trials for acute myeloid leukemia. This platform approach addresses cancers with limited existing treatment options.